Supplementary reference

1. Liu Y, Zhou LS, Xu XM, Deng LQ, Xiao QK. Association of Dietary Intake of Folate, Vitamin B6 and B12

and MTHFR Genotype with Breast Cancer Risk. Asian Pac J Cancer Prev. 2013;14:5189–92.

2. Yousef AM, Shomaf M, Berger S, Ababneh N, Bobali Y, Ali D, Al-Hasan S, Diab O, Ismail S. Allele and

Genotype Frequencies of the Polymorphic Methylenetetrahydrofolate Reductase and Colorectal Cancer

among Jordanian Population. Asian Pac J Cancer Prev. 2013;14:4559–65.

3. Akilzhanova A, Nurkina Z, Momynaliev K, Ramanculov E, Zhumadilov Z, Rakhypbekov T, Hayashida N,

Nakashima M, Takamura N. Genetic profile and determinants of homocysteine levels in Kazakhstan patients

with breast cancer. Anticancer Res. 2013;33:4049–59.

4. Vylliotis A, Yapijakis C, Nkenke E, Nisyrios T, Avgoustidis D, Adamopoulou M, Ragos V, Vassiliou S,

Koronellos N, Vairaktaris E. Effect of thrombosis-related gene polymorphisms upon oral cancer: a regression

analysis. Anticancer Res. 2013;33:4033–9.

5. Hosseini-Asl SS, Pourfarzi F, Barzegar A, Mazani M, Farahmand N, Niasti E, Yazdanbod A, Didevar R,

Akhavan H, Malekzadeh R. Decrease in gastric cancer susceptibility by MTHFR C677T polymorphism in

Ardabil Province, Iran. Turk J Gastroenterol. 2013;24:117–21.

6. Ashmore JH, Lesko SM, Muscat JE, Gallagher CJ, Berg AS, Miller PE, Hartman TJ, Lazarus P. Association

of dietary and supplemental folate intake and polymorphisms in three FOCM pathway genes with colorectal

cancer in a population-based case–control study. Genes Chromosomes Cancer. 2013;52:945–53.

7. Qu HH, Cui LH, Wang K, Wang P, Song CH, Wang KJ, Zhang JY, Dai LP. The Methylenetetrahydrofolate

Reductase C677T Polymorphism Influences Risk of Esophageal Cancer in Chinese. Asian Pac J Cancer Prev.

2013;14:3163–8.

8. Ouerhani S1, Rouissi K, Marrakchi R, Ben Slama MR, Sfaxi M, Chebil M, ElGaaied AB. Combined effect of

NAT2, MTR nd MTHFR genotypes and tobacco on bladder cancer susceptibility in Tunisian population.

Cancer Detect Prev. 2009;32:395–402.

9. Heijmans BT1, Boer JM, Suchiman HE, Cornelisse CJ, Westendorp RG, Kromhout D, Feskens EJ, Slagboom

PE. A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased

risk of cancer. Cancer Res. 2003;63:1249–53.

10. de Vogel S, Meyer K, Fredriksen A, Ulvik A, Ueland PM, Nygård O, Vollset SE, Tell GS, Tretli S, Bjørge T.

Serum folate and vitamin B12 concentrations in relation to prostate cancer risk–a Norwegian

population-based nested case–control study of 3000 cases and 3000 controls within the JANUS cohort. Int J

Epidemiol. 2013;42:201–10.

11. da Costa DM, de Lima GP, Faria MH, Rabenhorst SH. Polymorphisms of folate pathway enzymes

(methylenetetrahydrofolate reductase and thymidylate synthase) and their relationship with thymidylate

synthase expression in human astrocytic tumors. DNA Cell Biol. 2012;31:57–66.

12. López-Cortés A1, Jaramillo-Koupermann G, Muñoz MJ, Cabrera A, Echeverría C, Rosales F, Vivar N,

Paz-y-Miño C. Genetic Polymorphisms in MTHFR (C677T, A1298C), MTR (A2756G) and MTRR (A66G)

Genes Associated With Pathological Characteristics of Prostate Cancer in the Ecuadorian Population. Am J

Med Sci. 2013;346:447–54.

13. Fernández-Peralta AM, Daimiel L, Nejda N, Iglesias D, Medina Arana V, González-Aguilera JJ. Association

of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic

characteristic of tumors, and response to chemotherapy. Int J Colorectal Dis. 2010;25:141–51.

14. Delgado-Plasencia L, Medina-Arana V, Bravo-Gutiérrez A, Pérez-Palma J, Álvarez-Argüelles H, Salido-Ruiz

E, Fernández-Peralta AM, González-Aguilera JJ. Impact of the MTHFR C677T polymorphism on colorectal

cancer in a population with low geneticvariability. Int J Colorectal Dis. 2013;28:1187–93.

15. Stevens VL, Rodriguez C, Sun J, Talbot JT, Thun MJ, Calle EE. No association of single nucleotide

polymorphisms in one-carbon metabolism genes with prostate cancer risk. Cancer Epidemiol Biomarkers

Prev, 2008;17:3612–4.

16. Silva RM, Fontes AC, Silva KA, Sant'Ana TA, Ramos FJ, Marques-Salles Tde J, Pombo-de-Oliveira MS,

Muniz MT. Polymorphisms involved in folate metabolism pathways and the risk of the development of

childhood acute leukemia. Genet Test Mol Biomarkers. 2013;17:147–52.

17. Collin SM1, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, Cox A, Davis M, Lane JA, Donovan J, Smith GD,

Neal DE, Hamdy FC, Gudmundsson J, Sulem P, Rafnar T, Benediktsdottir KR, Eeles RA, Guy M, Kote-Jarai

Z; UK Genetic Prostate Cancer Study Group, Morrison J, Al Olama AA, Stefansson K, Easton DF, Martin

RM. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based

nested case–control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev.

2009;18:2528–39.

18. Li R, Wang R, Li Y, Li X, Feng Y, Li Y, Jiang C. Association study on MTHFR polymorphisms and

meningioma in northern China. Gene. 2013;516:291–3.

19. Fard-Esfahani P, Mohammadi Torbati P, Hashemi Z, Fayaz S, Golkar M. Analysis of relation between C677T

genotype in MTHFR gene and prostatic cancer in Iranian males. Acta Med Iran. 2012;50:657–63.

20. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH,

Rozen R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal

cancer. Cancer Res. 1997;57:1098–102.

21. Saberi S, Zendehdel K, Jahangiri S, Talebkhan Y, Abdirad A, Mohajerani N, Bababeik M, Karami N, Esmaili

M, Oghalaie A, Hassanpour P, Amini N, Mohagheghi MA, Eshagh Hossieni M, Mohammadi M. Impact of

methylenetetrahydrofolate reductase C677T polymorphism on the risk of gastric cancer and its interaction

with Helicobacter pylori infection. Iran Biomed J. 2012;16:179–84.

22. Nasr AS, Sami RM, Ibrahim NY. Methylenetetrahydrofolate reductase gene polymorphisms (677C > T and

1298A > C) in Egyptian patients with non-Hodgkin lymphoma. J Cancer Res Ther. 2012;8:355–60.

23. de Cássia Carvalho Barbosa R, da Costa DM, Cordeiro DE, Vieira AP, Rabenhorst SH. Interaction of MTHFR

C677T and A1298C, and MTR A2756G gene polymorphisms in breast cancer risk in a population in

Northeast Brazil. Anticancer Res. 2012;32:4805–11.

24. Promthet S, Pientong C, Ekalaksananan T, Songserm N, Poomphakwaen K, Chopjitt P, Wiangnon S,

Tokudome S. Risk factors for rectal cancer and methylenetetrahydrofolate reductase polymorphisms in a

population in Northeast Thailand. Asian Pac J Cancer Prev. 2012;13:4017–23.

25. Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, Chen J, Willett WC, Selhub J, Hennekens CH,

Gravel R, Rozen R. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin

B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 1999;8:825–9.

26. Diakite B, Tazzite A, Hamzi K, Jouhadi H, Nadifi S. Methylenetetrahydrofolate reductase C677T

polymorphism and breast cancer risk in Moroccan women. Afr Health Sci. 2012;12:204–9.

27. Mandal RK, Nissar K, Mittal RD. Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of

prostate cancer: a study from North India. Mol Biol Rep. 2012;39:11145–52.

28. Jiang N, Zhu X, Zhang H, Wang X, Zhou X, Gu J, Chen B, Ren J. The relationship between

methylenetetrahydrofolate reductase polymorphism and hematological malignancy. Clin Lab.

2014;60:767–74.

29. Cheng Z, Wang W, Dai LL, Kang Y. MTHFR C667T polymorphism association with lung cancer risk in

Henan province: a case–control study. Asian Pac J Cancer Prev. 2012;13:2491–4.

30. Kobayashi LC, Limburg H, Miao Q, Woolcott C, Bedard LL, Massey TE, Aronson KJ. Folate intake, alcohol

consumption, and the methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism: influence

on prostate cancer risk and interactions. Front Oncol. 2012;2:100.

31. Couvert P, Carrié A, Tezenas du Montcel S, Vaysse J, Sutton A, Barget N, Trinchet JC, Beaugrand M, Ganne

N, Giral P, Chelly J. Insulin-like growth factor 2 gene methylation in peripheral blood mononuclear cells of

patients with hepatitis C related cirrhosis or hepatocellular carcinoma. Clin Res Hepatol Gastroenterol.

2012;36:345–51.

32. Wu XY, Ni J, Xu WJ, Zhou T, Wang X. Interactions between MTHFR C677T-A1298C variants and folic acid

deficiency affect breast cancer risk in a Chinese population. Asian Pac J Cancer Prev. 2012;13:2199–206.

33. Yin G, Ming H, Zheng X, Xuan Y, Liang J, Jin X. Methylenetetrahydrofolate reductase C677T gene

polymorphism and colorectal cancer risk: A case-control study. Oncol Lett. 2012;4:365–369.

34. Akram M, Malik FA, Kayani MA. Mutational analysis of the MTHFR gene in breast cancer patients of

Pakistani population. Asian Pac J Cancer Prev. 2012;13:1599–603.

35. Beebe-Dimmer JL, Iyer PT, Nriagu JO, Keele GR, Mehta S, Meliker JR, Lange EM, Schwartz AG, Zuhlke

KA, Schottenfeld D, Cooney KA. Genetic variation in glutathione S-transferase omega-1, arsenic

methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a

case–control study. Environ Health. 2012;11:43.

36. Amigou A, Rudant J, Orsi L, Goujon-Bellec S, Leverger G, Baruchel A, Bertrand Y, Nelken B, Plat G, Michel

G, Haouy S, Chastagner P, Ducassou S, Rialland X, Hémon D, Clavel J. Folic acid supplementation, MTHFR

and MTRR polymorphisms, and the risk of childhood leukemia: the ESCALE study (SFCE). Cancer Causes

Control. 2012;23:1265–77.

37. Jakubowska A, Rozkrut D, Antoniou A, Hamann U, et al. Association of PHB 1630 C>T and MTHFR 677

C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a

multicenter study. Br J Cancer. 2012;106:2016–24.

38. Orjuela MA1, Cabrera-Muñoz L, Paul L, Ramirez-Ortiz MA, Liu X, Chen J, Mejia-Rodriguez F,

Medina-Sanson A, Diaz-Carreño S, Suen IH, Selhub J, Ponce-Castañeda MV. Risk of retinoblastoma is

associated with a maternal polymorphism in dihydrofolatereductase (DHFR) and prenatal folic acid intake.

Cancer. 2012;118:5912–9.

39. Zhang L, Liu W, Hao Q, Bao L, Wang K. Folate intake and methylenetetrahydrofolate reductase gene

polymorphisms as predictive and prognostic biomarkers for ovarian cancer risk. Int J Mol Sci.

2012;13:4009–20.

40. Lordelo GS, Miranda-Vilela AL, Akimoto AK, Alves PC, Hiragi CO, Nonino A, Daldegan MB,

Klautau-Guimarães MN, Grisolia CK. Association between methylene tetrahydrofolate reductase and

glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population.

Genet Mol Res. 2012;11:1013–26.

41. Ozdemir S, Silan F, Hasbek Z, Uludag A, Atik S, Erselcan T, Ozdemir O. Increased T-allele frequency of 677

C>T polymorphism in the methylenetetrahydrofolate reductase gene in differentiated thyroid carcinoma.

Genet Test Mol Biomarkers. 2012;16:780–4.

42. Gao S, Liu N, Ma Y, Ying L. Methylenetetrahydrofolate reductase gene polymorphisms as predictive and

prognostic biomarkers in ovarian cancer risk. Asian Pac J Cancer Prev. 2012;13:569–73.

43. Ragasudha PN, Thulaseedharan JV, Wesley R, Jayaprakash PG, Lalitha P, Pillai MR. A case–control

nutrigenomic study on the synergistic activity of folate and vitamin B12 in cervical cancer progression. Nutr

Cancer. 2012;64:550–8.

44. Nikbakht M, MalekZadeh K, Kumar Jha A, Askari M, Marwaha RK, Kaul D, Kaur J. Polymorphisms of

MTHFR and MTR genes are not related to susceptibility to childhood ALL in North India. Exp Oncol.

2012;34:43–8.

45. Hussain SR, Naqvi H, Raza ST, Ahmed F, Babu SG, Kumar A, Zaidi ZH, Mahdi F. Methylenetetrahydrofolate

reductase C677T genetic polymorphisms and risk of leukaemia among the North Indian population. Cancer

Epidemiol. 2012;36:e227–31.

46. Arslan S, Karadayi S, Yildirim ME, Ozdemir O, Akkurt I. The association between

methylene-tetrahydrofolate reductase gene polymorphism and lung cancer risk. Mol Biol Rep.

2011;38:991–6.

47. Lajin B, Alhaj Sakur A, Ghabreau L, Alachkar A. Association of polymorphisms in one-carbon metabolizing

genes with breast cancer risk in Syrian women. Tumour Biol. 2012;33:1133–9.

48. Lee JE, Wei EK, Fuchs CS, Hunter DJ, Lee IM, Selhub J, Stampfer MJ, Willett WC, Ma J, Giovannucci E.

Cancer Causes Control. Plasma folate, methylenetetrahydrofolate reductase (MTHFR), and colorectal cancer

risk in three large nested case–control studies. 2012;23:537–45.

49. Küçükhüseyin Ö, Kurnaz Ö, Akadam-Teker AB, Narter F, Yılmaz-Aydoğan H, İsbir T. Effects of the MTHFR

C677T polymorphism on prostate specific antigen and prostate cancer. Asian Pac J Cancer Prev.

2011;12:2275–8.

50. Zhao P, Lin F, Li Z, Lin B, Lin J, Luo R. Folate intake, methylenetetrahydrofolate reductase polymorphisms,

and risk of esophageal cancer. Asian Pac J Cancer Prev. 2011;12:2019–23.

51. Hosseini M, Houshmand M, Ebrahimi A. MTHFR polymorphisms and breast cancer risk. Arch Med Sci.

2011;7:134–7.

52. Kim J, Cho YA, Kim DH, Lee BH, Hwang DY, Jeong J, Lee HJ, Matsuo K, Tajima K, Ahn YO. Dietary

intake of folate and alcohol, MTHFR C677T polymorphism, and colorectal cancer risk in Korea. Am J Clin

Nutr. 2012;95:405–12.

53. Matsuo K, Suzuki R, Hamajima N, Ogura M, Kagami Y, Taji H, Kondoh E, Maeda S, Asakura S, Kaba S,

Nakamura S, Seto M, Morishima Y, Tajima K. Association between polymorphisms of folate- and

methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood. 2001;97:3205–9.

54. Huang GL, Wang SK, Su M, Wang TT, Cai HZ, Yin H, Sun GJ. Serum folate, MTHFR C677T polymorphism

and esophageal squamous cell carcinoma risk. Biomed Environ Sci. 2013;26:1008–12.

55. Pawlik P, Mostowska A, Lianeri M, Sajdak S, Kędzia H, Jagodzinski PP. Folate and choline metabolism gene

variants in relation to ovarian cancer risk in the Polish population. Mol Biol Rep. 2012;39:5553–60.

56. Carvalho Barbosa Rde C, Menezes DC, Freire TF, Sales DC, Alencar VH, Rabenhorst SH. Associations of

polymorphisms of folate cycle enzymes and risk of breast cancer in a Brazilian population are age dependent.

Mol Biol Rep. 2012;39:4899–907.

57. Jakovljevic K, Malisic E, Cavic M, Radulovic S, Jankovic R. Association between methylenetetrahydrofolate

reductase polymorphism C677T and risk of chronic myeloid leukemia in Serbian population. Leuk

Lymphoma. 2012;53:1327–30.

58. Izmirli M, Inandiklioglu N, Abat D, Alptekin D, Demirhan O, Tansug Z, Bayazit Y. MTHFR gene

polymorphisms in bladder cancer in the Turkish population. Asian Pac J Cancer Prev. 2011;12:1833–5.

59. Ajaz S, Khaliq S, Hashmi A, Naqvi SA, Rizvi SA, Mehdi SQ. Polymorphisms in the methylene

tetrahydrofolate reductase gene and their unique combinations are associated with an increased susceptibility

to the renal cancers. Genet Test Mol Biomarkers. 2012;16:346–52.

60. Onur E, Kurdal AT, Tugrul B, Iskesen I, Dundar P, Taneli F, Ulman C, Var A. Is genetic screening necessary

for determining the possibility of venous thromboembolism in cancer patients? Med Princ Pract.

2012;21:160–3.

61. Galbiatti AL, da Silva LM, Ruiz-Cintra MT, Raposo LS, Maníglia JV, Pavarino EC, Goloni-Bertollo EM.

Association between 11 genetic polymorphisms in folate-metabolising genes and head and neck cancer risk.

Eur J Cancer. 2012;48:1525–31.

62. Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y. Methylenetetrahydrofolate reductase polymorphisms and

interaction with smoking and alcohol consumption in lung cancer risk: a case–control study in a Japanese

population. BMC Cancer. 2011;11:459.

63. Azhar MR, Rahimi Z, Vaisi-Raygani A, Akramipour R, Madani H, Rahimi Z, Parsian A. Lack of association